Laboratory confirmed COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Group A receives standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 and oral famotidine 160 mg (Manufactured by Che
Sponsors
Bandare-abbas University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All COVID-19 patients whose disease has been confirmed by the PCR test for SARS-Cov-2. Signing the written consent of the study participant.
Exclusion criteria
Exclusion criteria: All Immunocompromised patients End stage renal disease Moderate renal insufficiency (creatinine clearance 30-50 mL/min) stage 4 sever chronic kidney disease requiring dialysis (i.e creatinine clearance 5 times the upper limit of normal. History of or evidence of QT prolongation on ECG examination History of psoriasis History of porphyria Pregnancy Use of oral contraceptive pills (OCP) Concomitant use of Dasatinib Concomitant use of Neratinib Concomitant use of Ozanimod Concomitant use of Pazopanib Concomitant use of Rilpivirine Concomitant use of Siponimod Concomitant use of Tizanidine Allergy to any study medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory rate. Timepoint: At the beginning of the study (before the intervention) and day 14 after the intervention or the day of patient's discharge. Method of measurement: Pulse oximeter.;Oxygen saturation state. Timepoint: At the beginning of the study (before the intervention) and day 14 after the intervention or the day of patient's discharge. Method of measurement: Pulse oximeter.;Lung infiltration status. Timepoint: At the beginning of the study (before the intervention) and day 14 after the intervention or the day of patient's discharge. Method of measurement: Chest X-ray.;Lactate Dehydrogenase(LDH) level's. Timepoint: At the beginning of the study (before the intervention) and day 14 after the intervention or the day of patient's discharge. Method of measurement: Pathobiology laboratory.;C-reactive protein(CRP) level's. Timepoint: At the beginning of the study (before the intervention) and day 14 after the intervention or the day of patient's discharge. Method of measurement: Pathobiology laboratory.;Lymphocyte count. Timepoint: At the beginning of the study (before the intervention) and day 14 after the intervention or the day of patient's discharge. Method of measurement: Pathobiology laboratory.;Platelet count. Timepoint: At the beginning of the study (before the intervention) and day 14 after the intervention or the day of patient's discharge. Method of measurement: Pathobiology laboratory. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient temperature status. Timepoint: At the beginning of the study (before the intervention), days 1 to 14 of the intervention or the time of the patient's discharge. Method of measurement: Digital thermometer.;Length of hospitalization. Timepoint: At the beginning of the study (before the intervention), days 1 to 14 of the intervention or the time of the patient's discharge. Method of measurement: Record patient information.;Length of Intensive Care Unit admission. Timepoint: At the beginning of the study (before the intervention), days 1 to 14 of the intervention or the time of the patient's discharge. Method of measurement: Record patient information. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDariush Hooshyar
Bandare-abbas University of Medical Sciences
Outcome results
None listed